KSQ Therapeutics
PrivateLast Round
Series C
Sep 28, 2018
Total Funding Raised
$156M
Company Overview
KSQ Therapeutics operates in Healthcare & Life Sciences and is based in Lexington, Massachusetts. Its latest recorded funding round was a Series C round in September 2018.
KSQ Therapeutics is a clinical-stage biotechnology company that utilizes its proprietary CRISPRomics® discovery engine to identify novel drug targets and develop treatments for solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
KSQ Therapeutics Comparables
Compare KSQ Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tango Therapeutics | 81% | |
| Maze Therapeutics | 80% | |
| Repare Therapeutics | 77% |
For institutional investors. Book with your work email.
KSQ Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 28, 2018 | ||||
| Series B | Oct 2, 2017 | ||||
| Seed | Oct 1, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
KSQ Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cowen Private Investments | Series C |
| Blue Owl Capital | Series C |
| Invus Opportunities | Series C |
| ARCH Venture Partners | Series B, Series C |
| Alexandria Venture Investments | Series B, Series C |
| Lilly Asia Ventures | Series C |
| Lilly Asia Ventures | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 5, 2025
Kristen Hege, M.D. appointed to the Board of Directors.
- Oct 2, 2017
$76M round led by Flagship Pioneering.
For institutional investors. Book with your work email.
KSQ Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about KSQ Therapeutics's valuation, stock price, and market status.
Is KSQ Therapeutics a public or private company?
KSQ Therapeutics is a private company.
What is the current stock price of KSQ Therapeutics?
KSQ Therapeutics is a private company, so its shares have no public market price. Caplight tracks KSQ Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is KSQ Therapeutics worth (valuation)?
Valuation information for KSQ Therapeutics is not publicly available.
Can I buy KSQ Therapeutics stock?
KSQ Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was KSQ Therapeutics's last funding round?
KSQ Therapeutics's most recent funding round was Series C on September 28, 2018.
Who are the main investors in KSQ Therapeutics?
Key investors in KSQ Therapeutics include Flagship Pioneering.
Will KSQ Therapeutics IPO soon?
No public IPO plans have been announced for KSQ Therapeutics.
How can I track KSQ Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in KSQ Therapeutics's shares on secondary markets.